Pentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?

Basit Öğe Kaydı
dc.contributor.authorBalin, Safak Ozer
dc.contributor.authorCabalak, Mehmet
dc.contributor.authorTartar, Ayse Sagmak
dc.contributor.authorKazanci, Ulku
dc.contributor.authorTelo, Selda
dc.contributor.authorDemirdag, Kutbeddin
dc.contributor.authorAkbulut, Ayhan
dc.date.accessioned2024-09-18T20:08:25Z
dc.date.available2024-09-18T20:08:25Z
dc.date.issued2021
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractBackground: Pentraxin-3 (PTX-3) is an important marker that plays a role in suppressing inflammation and tissue repair. The aim of this study is to investigate the diagnostic and prognostic characteristics of PTX-3 in chronic hepatitis B (CHB) patients and the relationship between PTX-3 levels and fibrosis. Methods: A total of 52 CHB patients and 40 healthy subjects were included in the study. All of the CHB patients underwent liver biopsy and were then scored using an Ishak histologic scoring system. Blood samples were collected to evaluate the PTX-3 levels. Results: Of the subjects who participated in the study, 53% were female. The PTX-3 levels were determined as 5.63 ng/mL in the control group, and as 0.88 ng/mL in the CHB patient group. PTX-3 levels were found to be 1.19 ng/mL in stage 1, 0.89 ng/mL in stage 2, 0.68 ng/mL in stage 3, and 0.55 ng/mL in stage 4. Of the CHB patients, 44.2% had significant fibrosis, while 55.7% were identified as not having significant fibrosis. The PTX-3 values were 0.64 and 1.0 ng/mL in patients with and without significant fibrosis, respectively. The cut-off value for PTX-3 in predicting the absence of significant fibrosis was estimated as 0.9 ng/mL. Conclusion: The CHB patients were found to have lower serum PTX-3 levels compared to the control group, and these levels decreased even further as the stage of fibrosis progressed. In addition, the significant decrease in PTX-3 levels in patients with stage 1 fibrosis compared to the control group shows that PTX-3 can be used as a non-invasive marker for the early detection of fibrosis (P <.001).en_US
dc.identifier.doi10.5152/tjg.2020.19378
dc.identifier.endpage585en_US
dc.identifier.issn2148-5607
dc.identifier.issue7en_US
dc.identifier.pmid34464321en_US
dc.identifier.scopus2-s2.0-85114182881en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage581en_US
dc.identifier.trdizinid513479en_US
dc.identifier.urihttps://doi.org/10.5152/tjg.2020.19378
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/513479
dc.identifier.urihttps://hdl.handle.net/20.500.12483/8818
dc.identifier.volume32en_US
dc.identifier.wosWOS:000692559500005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic hepatitis Ben_US
dc.subjectfibrosisen_US
dc.subjectPentraxin-3en_US
dc.titlePentraxin-3: A Novel Marker for Indicating Liver Fibrosis in Chronic Hepatitis B Patients?en_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
854.55 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu